Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.35 USD
-0.49 (-8.39%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $5.36 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -94.65 | -86.56 | -84.04 | -75.44 |
Depreciation/Amortization & Depletion | NA | 3.66 | 3.72 | 3.32 | 2.72 |
Net Change from Assets/Liabilities | NA | -5.52 | -10.60 | 12.09 | 3.75 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -26.55 | -6.10 | 11.27 | 8.71 |
Net Cash From Operating Activities | NA | -123.07 | -99.54 | -57.36 | -60.25 |
Property & Equipment | NA | -1.24 | -1.25 | -3.34 | -12.53 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 68.43 | -51.41 | 50.00 | 0.79 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 67.19 | -52.65 | 46.66 | -11.73 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 119.98 | 70.82 | 103.78 | 66.20 |
Issuance (Repayment) of Debt | NA | -0.29 | -0.27 | 39.38 | -0.21 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 11.36 | -0.04 | -0.21 | 0.00 |
Net Cash from Financing Activities | NA | 131.05 | 70.51 | 142.95 | 65.99 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 75.17 | -81.68 | 132.25 | -6.00 |
Cash at Beginning of Period | NA | 95.39 | 177.07 | 44.82 | 50.81 |
Cash at End of Period | NA | 170.55 | 95.39 | 177.07 | 44.82 |
Diluted Net EPS | NA | -7.49 | -13.80 | -18.20 | -18.80 |
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -100.19 | -60.05 | -23.79 | -94.65 |
Depreciation/Amortization & Depletion | NA | 2.32 | 1.57 | 0.77 | 3.66 |
Net Change from Assets/Liabilities | NA | -1.20 | 0.59 | -7.20 | -5.52 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 7.92 | -1.40 | -6.68 | -26.55 |
Net Cash From Operating Activities | NA | -91.15 | -59.29 | -36.90 | -123.07 |
Property & Equipment | NA | -0.23 | -0.23 | -0.24 | -1.24 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 36.05 | 7.41 | -25.51 | 68.43 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 35.82 | 7.18 | -25.75 | 67.19 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.14 | 0.14 | 0.00 | 119.98 |
Issuance (Repayment) of Debt | NA | -0.06 | -0.06 | -0.05 | -0.29 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 11.36 |
Net Cash from Financing Activities | NA | 0.08 | 0.09 | -0.05 | 131.05 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -55.25 | -52.03 | -62.70 | 75.17 |
Cash at Beginning of Period | NA | 170.55 | 170.55 | 170.55 | 95.39 |
Cash at End of Period | NA | 115.31 | 118.53 | 107.85 | 170.55 |
Diluted Net EPS | NA | -1.43 | -1.30 | -0.85 | 5.12 |